Associated tags: Patient, Prime editing, Gene editing, Pharmaceutical industry, Vaccine
Locations: NEW YORK, NY, UNITED STATES, CF, TD, TIMES SQUARE, BAY, FL, CAMBRIDGE, MA, US, BALTIMORE
Liver,
Bachelor of Science,
Biotechnology,
Anticalin,
Foghorn,
Research,
University,
S.A.C. Capital Advisors,
Therapy,
CIBC World Markets,
Patient,
Management CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.
Key Points:
- CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.
- A seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company.
- “I am delighted to welcome Allan to Prime Medicine.
- He brings tremendous financial, operational and leadership experience in the life sciences space, as well as a proven track record developing and implementing multi-pronged strategies to finance a diverse pipeline and broad platform,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m.
Key Points:
- CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 2:15 p.m. PT (5:15 p.m.
- ET) in San Francisco, CA.
- A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com.
- A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation.
Retrieved on:
Wednesday, November 8, 2023
Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences:
Key Points:
- Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences:
Stifel Healthcare Conference: Fireside Chat by Keith Gottesdiener, M.D., President and Chief Executive Officer, on Tuesday, November 14, 2023, at 4:10 p.m.
- Jefferies London Healthcare Conference: Fireside Chat by Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer, on Thursday, November 16, 2023, at 1:30 p.m. GMT (8:30 a.m.
- Live audio webcasts of both presentations will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com .
- Replays of each webcast will be available on the Prime Medicine website for 30 days following each presentation.
Gene editing,
International Symposium on Endovascular Therapy,
FDA,
Research,
Food,
Rhodopsin,
Human,
Congress,
Fragile X syndrome,
G&A,
Liver,
CFTR,
Chromosomal translocation,
Regulation of tobacco by the U.S. Food and Drug Administration,
Cell,
Initial,
R,
Society,
ASH,
RHO,
Tissue,
Lung,
Cystic fibrosis,
Prime editing,
Gene,
Composition,
Abstract,
LNP,
Eye,
Safety,
European Society of Clinical Microbiology and Infectious Diseases,
Investment,
CGD,
Patient,
Retina,
NHP,
Patent,
D,
Vaccine,
Pharmaceutical industry,
Fine chemical,
Beef cattle,
Video game,
Cryptocurrency,
IND CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
Key Points:
- 11,795,452 --
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
- Together, these encouraging results mark meaningful progress toward the clinic and support our strategy of simultaneously advancing multiple programs forward.
- In August 2023, Prime Medicine received Rare Pediatric Drug designation (RPDD) from the U.S. Food and Drug Administration (FDA) for PM359.
- Year-to-date, Prime Medicine continues to make significant progress, executing against key initiatives to drive its Prime Editing platform forward.
Well,
Gene editing,
NHP,
RNA,
Biotechnology,
Congress,
SLC37A4,
Liver,
Cell,
Allele,
Hypoglycemia,
Caregiver,
Disease,
Gene,
Messenger,
LNP,
ESGCT,
Animal,
European Society of Gene and Cell Therapy,
Patient,
Mutation,
Vaccine,
Marketing,
Hepatocyte CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology Company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of liver-targeted Prime Editors to efficiently and precisely correct one of the most prevalent disease-causing mutations of glycogen storage disease 1b (GSD1b) in non-human primates (NHP) and mouse models. The data were presented today at the European Society of Gene and Cell Therapy (ESGCT) 2023 Congress in Brussels, Belgium.
Key Points:
- The data were presented today at the European Society of Gene and Cell Therapy (ESGCT) 2023 Congress in Brussels, Belgium.
- “The data presented today are highly encouraging, both for patients and caregivers impacted by GSD1b, as well as for Prime Medicine and the field of gene editing,” said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine.
- “These data are the first Prime Editing data in NHPs and provide further proof-of-concept for our Prime Editing approach to potentially address a wide range of diseases, in this case, by targeting a specific gene with a liver-directed LNP.
- In today’s presentation at ESGCT, Prime Medicine highlighted data from in vivo rodent and NHP studies with its Prime Editor targeting the p.L348fs mutation.
Retrieved on:
Tuesday, October 24, 2023
Well,
International Symposium on Endovascular Therapy,
AAV,
Rhodopsin,
RNA,
Congress,
Photoreceptor,
PCR,
Research,
Retinal,
RHO,
Disease,
Glial fibrillary acidic protein,
Retina,
GFAP,
Eye,
Paratriathlon,
Patient,
Gene expression,
Vaccine CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of Prime Editors to efficiently and precisely correct the predominant mutations that cause rhodopsin associated autosomal dominant retinitis pigmentosa (RHO adRP). The data were presented today at the International Symposium on Retinal Degeneration 2023 Congress (RD2023) in Costa del Sol, Spain.
Key Points:
- The data were presented today at the International Symposium on Retinal Degeneration 2023 Congress (RD2023) in Costa del Sol, Spain.
- “The data presented today are the first proof-of-concept data for Prime Editing’s application in treating ophthalmological indications, and highlight the ability of Prime’s novel, dual AAV delivery platform to efficiently deliver Prime Editors to the eye,” said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine.
- In today’s presentation at RD2023, Prime Medicine shared findings from in vivo studies in humanized mice with its Prime Editors targeting these prevalent RHO mutations.
- Efficient delivery of Prime Editors by dual AAV to human (retinal explants) and murine (in vivo) photoreceptors.
Retrieved on:
Tuesday, October 17, 2023
Palilalia,
LNP,
CFTR,
Liver disease,
Safety,
Hotspot,
Cystic fibrosis,
Prime editing,
Science,
Lung,
Patient,
Pharmaceutical industry,
Vaccine Title: Prime Editing in Hematopoietic Diseases and Beyond: Efficacy and Safety
Key Points:
- Title: Prime Editing in Hematopoietic Diseases and Beyond: Efficacy and Safety
Overview of Prime Medicine’s comprehensive proprietary approach to off-target analysis, including details of off-target analyses from Prime Medicine’s programs.
- First in vivo proof-of-concept data in adRP, including mutational hotspot Prime Editing, initial safety data for lead Retinitis Pigmentosa program, and highlights from Prime Medicine’s modular retinal delivery platform.
- Prime Medicine’s liver-targeted LNP and all-RNA delivery platforms, in vivo proof-of-concept data, and first non-human primate data for Prime Editing in GSD1b.
- Additional data from Prime Medicine’s liver-targeted LNP and all-RNA delivery platforms; in vivo proof-of-concept data in GSD1b program; and expanded non-human primate results for Prime Editing in GSD1b.
Retrieved on:
Tuesday, September 19, 2023
Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences:
Key Points:
- Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences:
BMO Biopharma Virtual Spotlight Series: Latest Advances in Genome / Epigenome Editing: Fireside chat on Tuesday, September 26, 2023, at 10:30 a.m.
- Jefferies Cell & Genetic Medicine Summit (New York, NY): Fireside chat on Wednesday, September 27, 2023, at 9:00 a.m.
- In addition, replays of the BMO fireside chat and Chardan panel discussion will become available after the presentations conclude.
- Replays of all webcasts will be available on the Prime Medicine website for 30 days following the presentation.
Retrieved on:
Thursday, August 31, 2023
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two upcoming investor conferences.
Key Points:
- CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two upcoming investor conferences.
- 2023 Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 7, 2023, at 11:00 a.m.
- Morgan Stanley Global Healthcare Conference: Fireside chat on Monday, September 11, 2023, at 11:20 a.m.
- Replays of all webcasts will be available on the Prime Medicine website for 30 days following the presentation.
Myelodysplastic syndrome,
Exercise,
Chronic granulomatous disease,
Partnership,
Gene,
SCIP,
Eye,
Immunotherapy,
G&A,
Toxicity,
Research,
Economics,
CD34,
Acute myeloid leukemia,
Transplant,
MDS,
Health,
AML,
Investment,
Patient,
Cancer,
Annual general meeting,
Cell,
CGD,
American Society of Gene and Cell Therapy,
Liver,
Prime editing,
HSC,
R,
Therapy,
CD117,
Society,
DSM-IV codes,
D,
Medical device,
Pharmaceutical industry,
Vaccine,
Video game,
Cryptocurrency,
IND CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the second quarter ended June 30, 2023.
Key Points:
- In May 2023, Prime Medicine presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.
- Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
Initiate investigational new drug (IND)-enabling studies for PM359 in CGD in 2023.
- Maximize Prime Editing’s broad therapeutic potential and create value through strategic business development that extends the reach and impact of Prime Editing to areas beyond Prime Medicine’s current areas of focus.
- Second Quarter 2023 Financial Results:
R&D Expenses: Research and development (R&D) expenses were $34.6 million for the three months ended June 30, 2023, as compared to $18.9 million for the three months ended June 30, 2022.
